8-K: Hologic Acquired by Blackstone & TPG for up to $79/Share

Hologic, Inc. announced a definitive agreement to be acquired by funds managed by Blackstone and TPG for up to $79 per share, including a contingent value right.

Summary

• Hologic, Inc. will be acquired by funds managed by Blackstone Inc. and TPG Capital in a transaction valued at up to $18.3 billion enterprise value.
• Hologic stockholders will receive $76.00 per share in cash at the closing of the merger.
• Stockholders will also receive one non-tradable contingent value right (CVR) per share, representing the right to receive up to an additional $3.00 in cash, payable in two installments of up to $1.50 each.
• CVR payments are contingent upon Hologic's Breast Health business achieving specific global revenue goals in fiscal years 2026 and 2027.
• The total potential consideration of up to $79.00 per share represents a premium of approximately 46% to Hologic's closing price on May 23, 2025, the last full trading day prior to media reports of a possible transaction.
• The transaction includes significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) and an affiliate of GIC.
• Hologic's Board of Directors unanimously approved the merger agreement and recommends that Hologic stockholders vote to approve the transaction.
• The merger agreement includes a 45-day 'go-shop' period, ending December 5, 2025, during which Hologic and its advisors may solicit alternative acquisition proposals.
• Upon completion of the transaction, Hologic's common stock will be delisted from the Nasdaq Stock Market LLC and deregistered under the Securities Exchange Act of 1934.
• Hologic will maintain its headquarters in Marlborough, Massachusetts, and continue to operate under the Hologic name and brand.

Sentiment

Score: 9

Explanation: The acquisition offers a substantial premium to shareholders with immediate cash value and potential upside through CVRs, reflecting strong confidence from leading private equity firms in Hologic's business and future growth prospects. The unanimous board approval and go-shop period further enhance the positive sentiment.

Positives

• Shareholders will receive a substantial premium of approximately 46% over Hologic's closing price on May 23, 2025, prior to media reports of a potential transaction.
• The deal provides immediate cash consideration of $76.00 per share, offering certainty of value to stockholders.
• The inclusion of a Contingent Value Right (CVR) offers potential additional upside of up to $3.00 per share based on the future performance of the Breast Health business.
• Hologic's Board of Directors unanimously approved the merger agreement, indicating strong internal support for the transaction.
• A 45-day 'go-shop' period allows Hologic to solicit and consider potentially superior alternative acquisition proposals.
• Blackstone and TPG have secured committed financing for the transaction, reducing financing risk.
• The partnership with Blackstone and TPG is expected to accelerate growth and enhance Hologic's ability to deliver medical technologies, with continued investment in product innovation.
• Hologic will retain its headquarters, name, and brand, suggesting continuity for operations and employees.

Negatives

• The Contingent Value Rights (CVRs) are non-tradable and contingent upon achieving specific revenue milestones, meaning the full $3.00 per share is not guaranteed and their value is uncertain.
• Hologic's common stock will be delisted from Nasdaq, resulting in a loss of public market liquidity for shareholders.
• The transaction may cause disruption to management time from ongoing business operations.
• There is a risk that Hologic stockholders may not approve the proposed transaction.
• The parties may not be able to satisfy all closing conditions in a timely manner or at all.
• The transaction could incur unexpected costs or expenses.
• There is a risk of litigation relating to the proposed transaction.
• The announcement could adversely affect Hologic's ability to retain and hire key personnel and maintain relationships with customers, vendors, partners, employees, and other business relationships.

Risks

• The timing, receipt, and terms of required governmental and regulatory approvals could delay the consummation of the proposed transaction or cause the parties to abandon it.
• The occurrence of any event, change, or other circumstances could give rise to the termination of the merger agreement.
• Hologic stockholders may not approve the proposed transaction.
• The parties to the merger agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all.
• Disruption of management time from ongoing business operations due to the proposed transaction.
• Announcements relating to the proposed transaction could have adverse effects on the market price of Hologic's common stock.
• Unexpected costs or expenses may result from the proposed transaction.
• Litigation relating to the proposed transaction is possible.
• The proposed transaction and its announcement could adversely affect Hologic's ability to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees, stockholders, and other business relationships, impacting operating results and business generally.
• Holders of the CVRs may receive less-than-anticipated payments due to various risks and uncertainties related to the Breast Health business.

Future Outlook

Hologic will not provide financial guidance for fiscal 2026 due to the pending transaction. The company expects to continue its leadership in women's health and accelerate growth with the resources and expertise of Blackstone and TPG, focusing on continued product innovation. The CVRs are contingent on achieving specific revenue milestones for the Breast Health business in fiscal years 2026 and 2027, with no assurance that any milestones will be achieved.

Management Comments

• Stephen P. MacMillan, Hologic's Chairman, President and Chief Executive Officer, stated: 'Today marks an exciting new chapter for Hologic as we join forces with the exceptional teams at Blackstone and TPG. With their resources, expertise and commitment to womens health, Blackstone and TPG will help accelerate our growth and enhance our ability to deliver critical medical technologies to customers and their patients around the world. This transaction delivers immediate and compelling value to Hologic stockholders, reflecting the dedication of our employees whose hard work has made this milestone possible.'
• Ram Jagannath, a Senior Managing Director at Blackstone, commented: 'Hologic is an outstanding global leader in advancing womens health, with a longstanding reputation for groundbreaking and high-quality medical device and diagnostic products. We have closely followed the Company for many years and long admired the positive impact its life-changing technologies have had for millions of patients worldwide. We are thrilled to partner with its highly talented and capable employees, alongside TPG, to further invest in Hologics continued product innovation and growth.'
• John Schilling, M.D., Co-Managing Partner of TPG Capital, added: 'Hologics innovation-driven medical products and technologies are advancing detection and care to improve health outcomes for women around the world. Investing behind healthcare innovation has been a core focus for TPG for decades, and Hologic represents a compelling opportunity to draw upon our deep thematic expertise to support the development of next-generation solutions that will continue to promote strong clinical results and enhance patient care. Were proud to partner with the Hologic team and Blackstone in this exciting new chapter.'

Industry Context

The acquisition by private equity firms Blackstone and TPG highlights a trend of private capital seeking to invest in established healthcare leaders, particularly in specialized segments like women's health and medical technology. This move suggests a belief in the long-term growth potential of Hologic's core businesses, especially Breast Health, and an intent to leverage private ownership to accelerate innovation and market penetration, potentially through increased R&D or strategic acquisitions, away from public market pressures. The involvement of sovereign wealth funds (ADIA, GIC) further underscores the attractiveness of stable, high-quality healthcare assets to large institutional investors.

Management Changes

Corporate Governance

Legal Proceedings

• The filing mentions the risk of 'any litigation relating to the proposed transaction'.
• The Company will promptly notify Parent of any stockholder litigation or Action against it or its Representatives arising out of or relating to the merger agreement or transactions contemplated.
• The Company will provide Parent an opportunity to review and comment on filings or responses to stockholder litigation and participate in the defense/settlement, requiring Parent's consent for any settlement.

Stakeholder Impact

• Shareholders: Will receive a significant cash premium and potential additional value through CVRs, but will lose their equity interest in a publicly traded company.
• Employees: Certain named executive officers received cash retention awards. For at least one year post-closing, continuing employees will receive no less favorable base salary, target cash bonus opportunities, and substantially comparable aggregate employee and fringe benefits. Severance benefits will be maintained for qualifying terminations within 24 months post-closing.
• Customers, Vendors, Partners: There is a risk that the proposed transaction and its announcement could have an adverse effect on Hologic's ability to maintain relationships with these key business contacts.
• Company (Hologic): Will become a wholly-owned subsidiary of Hopper Parent Inc., delisted from Nasdaq, but will maintain its headquarters, name, and brand, with an expectation of accelerated growth and enhanced ability to deliver medical technologies through new ownership resources.

Next Steps

• Hologic will prepare and file a preliminary proxy statement with the SEC as promptly as practicable, and in no event later than December 5, 2025.
• Hologic will use reasonable best efforts to have the proxy statement cleared by the SEC as promptly as practicable.
• Hologic plans to mail a definitive proxy statement to its stockholders.
• Hologic will convene a Company Stockholders Meeting to consider and vote upon the approval of the merger agreement.
• The parties must obtain required governmental and regulatory approvals, including under the HSR Act and other antitrust laws, and satisfy the CFIUS waiting period.
• Hologic plans to report its financial results for the fourth quarter of fiscal 2025 via press release on November 3, 2025.
• Hologic plans to file its Form 10-K for fiscal 2025 with the SEC in late November.
• The 45-day 'go-shop' period will conclude at 12:01 A.M. (New York time) on December 5, 2025.
• At or prior to the Effective Time, Parent, the Company, and a Rights Agent will enter into a Contingent Value Rights Agreement.
• Parent may commence one or more offers to purchase, offers to exchange, or solicitations of consents with respect to any or all of the outstanding aggregate principal amount of the Existing Notes.
• If requested by Parent, Hologic will issue one or more notices of redemption for all or a portion of the outstanding aggregate principal amount of its Existing Notes.
• If the merger is consummated, Hologic's common stock will be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934.

Key Dates

Recommendation

The acquisition offers a substantial premium of 46% over the pre-announcement trading price, providing immediate and compelling value to shareholders. The additional contingent value right (CVR) offers further upside potential based on the performance of the Breast Health business. The unanimous board approval and the inclusion of a go-shop period suggest a well-vetted deal with potential for even higher offers. For investors, this represents a strong opportunity for a significant, near-term return.

Keywords

Hologic, HOLX, Blackstone, TPG Capital, Acquisition, Merger, Contingent Value Right, CVR, Womens Health, Medical Technology, Private Equity, Healthcare, Breast Health